Biocon Limited (BOM:532523)
India
· Delayed Price · Currency is INR 312.00
-14.40 (-4.41%)
At close: Apr 25, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 |
| Biosimilars | 88.18B |
Log In |
Log In |
Log In |
Log In |
| Biosimilars Growth | 58.61% |
Log In |
Log In |
Log In |
Log In |
| Research | 34.37B |
Log In |
Log In |
Log In |
Log In |
| Research Growth | 9.50% |
Log In |
Log In |
Log In |
Log In |
| Generics | 25.00B |
Log In |
Log In |
Log In |
Log In |
| Generics Growth | 1.80% |
Log In |
Log In |
Log In |
Log In |
| Novels | - |
Log In |
Log In |
Log In |
Log In |
| Novels Growth | - |
Log In |
Log In |
Log In |
Log In |
| Biologics | - |
Log In |
Log In |
Log In |
Log In |
| Biologics Growth | - |
Log In |
Log In |
Log In |
Log In |
| Branded Formulations | - |
Log In |
Log In |
Log In |
Log In |
| Branded Formulations Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 |
| United States | 64.55B |
Log In |
Log In |
Log In |
Log In |
| United States Growth | 55.80% |
Log In |
Log In |
Log In |
Log In |
| European Union (Including Ireland) | 35.17B |
Log In |
Log In |
Log In |
Log In |
| Rest of the World | 31.76B |
Log In |
Log In |
Log In |
Log In |
| Rest of the World Growth | -24.01% |
Log In |
Log In |
Log In |
Log In |
| India | 16.08B |
Log In |
Log In |
Log In |
Log In |
| India Growth | -3.93% |
Log In |
Log In |
Log In |
Log In |
| Ireland | - |
Log In |
Log In |
Log In |
Log In |
| Ireland Growth | - |
Log In |
Log In |
Log In |
Log In |